Lutetium Lu-177 PSMA I&T Injection, Xofigo 1100 kBq/mL solution for injection clinical trials

DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

This study looks at a new way to treat prostate cancer that has spread to the bones. It combines two types of radiation treatment, Lutetium-177 PSMA and Radium-223, given one after the other. We want to see if this treatment is safe and practical for men after their initial cancer treatment.